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ABSTRACT
Objective Compare changes in lipids and lipid-
associated cardiovascular (CV) risk markers in patients
with rheumatoid arthritis (RA) treated with tocilizumab
or adalimumab.
Methods Post-hoc analysis was performed in patients
with RA who received tocilizumab intravenously every
4 weeks or adalimumab subcutaneously every 2 weeks
for 24 weeks in the ADACTA trial. Lipid and lipid-
associated CV risk biomarkers, including high-density
lipoprotein-associated serum amyloid-A (HDL-SAA),
secretory phospholipase A2 IIA (sPLA2 IIA) and lipoprotein
(a) (Lp(a)), were measured at baseline and at week 8.
Results The study included 162 patients treated with
tocilizumab and 162 patients treated with adalimumab;
HDL-SAA and sPLA2 IIA were measured in a
subpopulation of 87 and 97 patients, respectively.
Greater increases in mean low-density lipoprotein
cholesterol (LDL-C) (0.46 mmol/L (95% CI 0.30 to 0.62)),
high-density lipoprotein cholesterol (HDL-C) (0.07 mmol/L
(0.001 to 0.14)), total cholesterol (TC) (0.67 mmol/L
(0.47 to 0.86)), triglycerides (0.24 mmol/L (0.10 to 0.38))
and TC:HDL ratio (0.27 (0.12 to 0.42)) occurred with
tocilizumab from baseline to 8 weeks. HDL-SAA, sPLA2
IIA and Lp(a) decreased more with tocilizumab than
adalimumab. Median changes from baseline to week 8
were –3.2 and –1.1 mg/L (p=0.0077) for HDL-SAA and
–4.1 and –1.3 ng/mL (p<0.0001) for sPLA2 IIA;
difference in adjusted means was –7.12 mg/dL
(p<0.0001) for Lp(a). Similar results were observed in
efﬁcacy responders and non-responders per American
College of Rheumatology and European League against
Rheumatism criteria.
Conclusion LDL-C and HDL-C increased more with
tocilizumab than adalimumab. HDL-SAA, sPLA2 IIA and
Lp(a) decreased more with tocilizumab. Lipid change
effects of interleukin-6 and tumour necrosis factor (TNF)
inhibition, manifest by their net impact on lipids and
lipoproteins, are not synonymous; the clinical signiﬁcance
is unclear and requires further study.
Trial registration number NCT01119859.; post-
results
INTRODUCTION
Patients with rheumatoid arthritis (RA) are at
increased risk of cardiovascular disease (CVD) com-
pared with the general population.1 2 Traditional
risk factors for CVD do not appear to fully explain
this increased risk,3 and additional factors, includ-
ing inﬂammation, may contribute to CVD risk in
RA.4 5 The impact of inﬂammation on lipid levels
is complex and may manifest as changes in total
cholesterol (TC) levels and in lipid particle–asso-
ciated proteins, such as serum amyloid A (SAA) and
secretory phospholipase A2 IIA (sPLA2 IIA); both
are identiﬁed biomarkers of increased cardiovascu-
lar (CV) risk.6–8 Patients with severe, untreated RA
may have very low lipid levels, which is paradoxical
when considering their increased risk of CVD.9 In
contrast, treatment of active disease can lead to
elevated levels of TC, low-density lipoprotein chol-
esterol (LDL-C) and high-density lipoprotein chol-
esterol (HDL-C) in conjunction with reduced levels
of inﬂammation.9
Lipoprotein(a) (Lp(a)) levels are increased in
patients with RA.10 The association of Lp(a) with
CVD in the general population has been assessed
through genetic and Mendelian randomisation
studies.11–13 These studies strongly point to Lp(a) as
a causal agent in the process of atherogenesis.11–14
Moderate early elevations in LDL-C, HDL-C and
triglyceride levels were reported in Phase II and
Phase III clinical trials of patients with RA treated
with the interleukin-6 (IL-6) receptor inhibitor toci-
lizumab (TCZ); the TC:HDL-C ratio either
decreased or remained unchanged.15 In contrast, a
decline in Lp(a) with TCZ treatment and a change
in HDL protein composition occurred.16 Lipid
changes have also been reported in patients with RA
treated with tumour necrosis factor (TNF)-α inhibi-
tors.17 Patients with RA treated with adalimumab
had increased HDL-C and apolipoprotein A1 levels,
with no change in LDL-C or triglyceride levels, and
improvement in atherogenic ratios.18 19 Data on the
effect of TNF-α blockers on Lp(a) are mixed,
though most did suggest a reduction.19–23 Described
here is a post-hoc analysis of data from a clinical
trial that compared IL-6 and TNF-α signalling inhib-
ition to assess the impact of these therapeutic strat-
egies on lipid-associated CV risk biomarkers and
their relationship to treatment response. The dearth
of such comparator trials despite an urgent need for
better understanding of any differential effects of
these agents on CV risk parameters makes this ana-
lysis important.
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PATIENTS AND METHODS
Patients
This post-hoc study included patients from the ADACTA trial
(ClinicalTrials.gov number NCT01119859). ADACTA was a
Phase IV study that assessed the efﬁcacy of TCZ as monotherapy
compared with adalimumab as monotherapy in adults who had
RA for ≥6 months and who were intolerant of or not good candi-
dates for continued use of methotrexate (MTX).24 A total of 326
patients were randomly assigned 1:1 to receive either TCZ 8 mg/
kg monotherapy intravenously every 4 weeks plus subcutaneous
placebo every 2 weeks or adalimumab 40 mg monotherapy sub-
cutaneously every 2 weeks plus intravenous placebo every
4 weeks for 24 weeks. Patients had to discontinue all synthetic
disease-modifying antirheumatic drugs (DMARDs) within an
appropriate washout period before baseline; any patient requir-
ing treatment with a synthetic or biological DMARD was with-
drawn from the study.24 Analyses of core lipids and Lp(a) were
performed in the ADACTA safety population, which included all
patients who received at least one dose of study medication and
had at least one post-dose safety assessment. Additional analyses
of lipid-associated CV risk biomarkers were performed in 184
patients (97 adalimumab, 87 TCZ) who consented to donate
serum bio-repository samples for further exploratory analysis
and who provided both baseline and week 8 samples. Week 8
samples provide a larger sample size than do later time points,
and previous studies have shown that lipid changes observed
after 6 weeks remain stable with continued TCZ treatment.25
Assessments
Core lipid panel (LDL-C, HDL-C, TC and triglycerides) and
lipid-associated CV risk biomarker levels (Lp(a), HDL-SAA and
sPLA2 IIA) were analysed in serum samples obtained at baseline
and at week 8. Week 8 was selected because of the limited availabil-
ity of bio-repository samples later in the study although data for
Lp(a) and core lipids were available for later time points. With
the exception of LDL, which was calculated using the formula
TC−HDL-C−(triglycerides/5), the core lipid panel was measured
using the β-quantiﬁcation method. The core lipid panel and Lp(a)
was analysed by Covance Central Laboratory Services (Indianapolis,
Indiana, USA). Assays for HDL-SAA and sPLA2 IIA levels were per-
formed at Paciﬁc Biometrics (Seattle, Washington, USA).
sPLA2 IIA was determined with the use of an enzyme
immunoassay (EIA) kit (Cayman Chemical, Ann Arbor, Michigan,
USA) by coupling a monoclonal capture antibody with detection
by acetylcholinesterase/Fab conjugate and 505-dithiobis 2-nitro-
benzoic acid (DTNB). EDTA serum Lp(a) (Denka Seiken,
Tokyo, Japan) was quantiﬁed using immunoturbidimetric assay
kits. These assays were performed with a Roche Modular P
autoanalyzer (Roche Diagnostics, Indianapolis, Indiana, USA).
For determination of HDL-SAA, serum HDL particles were
isolated by polyethylene glycol 8000 (PEG-8000; Promega,
Madison, Wisconsin, USA) precipitation, as described by Chiba
et al.26 Brieﬂy, equal volumes of 13.0% PEG (P-4463;
Sigma-Aldrich, St Louis, Missouri, USA) were mixed to precipi-
tate non-HDL proteins and lipoproteins. After centrifugation
for 5 min at 18 000 g, supernate SAA was determined by EIA
(Abazyme; Needham, Massachusetts, USA). An anti-SAA mono-
clonal capture and a horseradish peroxidase-conjugated poly-
clonal antibody were used with 3,30,5,50-tetramethylbenzidine
(TMB) detection.
Statistical analyses
Differences between TCZ and adalimumab in change from base-
line to week 8 in LDL-C, HDL-C, TC, triglycerides, TC:HDL
ratio and Lp(a) were assessed using a post-hoc analysis of covari-
ance model adjusted for baseline laboratory parameters.
Differences in change from baseline to week 8 in HDL-SAA and
sPLA2 IIA were assessed using the Kruskal–Wallis test. Log trans-
formation of the data was investigated because of the skewed distri-
bution of these two parameters. The transformation did not allow
the parameters to be normally distributed; therefore, the non-
parametric statistical method of the Kruskal–Wallis test was used to
account for the skewed distribution of the data. Change from base-
line to week 8 was summarised and was also split by efﬁcacy
responders. Week 24 American College of Rheumatology (ACR)
20, ACR50 and European League against Rheumatism (EULAR)
good/moderate responders and non-responders were used to
analyse HDL-SAA, sPLA2 IIA and Lp(a) levels by efﬁcacy. Change
in Lp(a) from >50 mg/dL at baseline to ≤50 mg/dL at week 8 was
summarised based on recommendations that suggest Lp(a) levels
should ideally be <50 mg/dL in patients at intermediate or high
risk of CVD/coronary heart disease (CHD).27 All statistical analyses
were post-hoc; therefore, no adjustments were made for multiple
testing, and no statistical signiﬁcance can be claimed.
RESULTS
The ADACTA safety population consisted of 324 patients who
were intolerant of MTX or for whom MTX was inappropriate.
The bio-repository population consisted of 184 patients from
the ADACTA safety population. Baseline demographics and
disease characteristics were similar between the two treatment
arms and between the safety and bio-repository populations (see
online supplementary table S1). Core lipid parameters, includ-
ing LDL-C, HDL-C, TC, triglyceride levels and TC:HDL ratio,
increased from baseline to week 8 with TCZ monotherapy;
numerically smaller changes were observed for these lipids with
adalimumab monotherapy.
Differences in mean (95% CI) change from baseline between
arms were as follows: 0.46 mmol/L (0.30 to 0.62; p<0.0001)
for LDL-C; 0.07 mmol/L (0.001 to 0.14; p=0.0453) for
HDL-C; 0.67 mmol/L (0.47 to 0.86; p<0.0001) for TC;
0.24 mmol/L (0.10 to 0.38; p=0.0008) for triglycerides and
0.27 (0.12 to 0.42; p=0.0005) for TC:HDL ratio (table 1).
Reductions in HDL-SAA levels were observed from baseline
to week 8 in patients treated with TCZ monotherapy and in
those treated with adalimumab monotherapy. A greater treat-
ment effect was observed in the TCZ group; median (IQR)
change from baseline to week 8 was –3.2 mg/L (–11.1, –1.0)
and –1.1 mg/L (–7.1, 0.6) for TCZ and adalimumab, respect-
ively (p=0.0077) (table 2 and ﬁgure 1A). Reductions in sPLA2
IIA levels were also observed with both TCZ and adalimumab
monotherapy, with greater reductions seen in the TCZ group;
median (IQR) change from baseline to week 8 was –4.1 ng/mL
(–7.8, –1.1) and –1.3 ng/mL (–2.9, 0.8) for TCZ and adalimu-
mab, respectively (p<0.0001) (table 2 and ﬁgure 1B). Greater
reductions in Lp(a) were observed in patients treated with TCZ
monotherapy than with adalimumab monotherapy; the differ-
ence in adjusted means (95% CI) was –7.12 mg/dL (–9.9 to
–4.4) (p<0.0001) (table 3 and ﬁgure 1C). Higher proportions
of patients who had baseline Lp(a) levels >50 mg/dL improved
(deﬁned as achieving Lp(a) levels ≤50 mg/dL) by week 8 in the
TCZ monotherapy group (11/21 patients (52.4%)) than in the
adalimumab monotherapy group (6/24 patients (25.0%)).
Changes in HDL-SAA, sPLA2 IIA and Lp(a) levels by efﬁcacy
response
Changes from baseline to week 8 in Lp(a), sPLA2 IIA and
HDL-SAA were also evaluated relative to efﬁcacy response.
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Greater reductions were seen in all three lipid-associated CV
risk biomarkers at week 8 in both efﬁcacy responders and non-
responders who received TCZ monotherapy than in those who
received adalimumab monotherapy. In ACR20 responders and
non-responders, median IQR changes from baseline to week 8
in HDL-SAA were –3.3 mg/L (–10.0, –1.0) and –3.1 mg/L
(–12.95, –1.15), respectively, with TCZ and –1.0 mg/L (–6.8,
0.55) and –1.1 mg/L (–8.7, 1.2), respectively, with adalimumab.
Similar trends were observed for ACR50 and EULAR good/
moderate responders and non-responders for HDL-SAA and for
sPLA2 IIA (table 4) and Lp(a) (table 5).
DISCUSSION
It was previously demonstrated that though LDL-C levels
increase in patients treated with TCZ, Lp(a) levels may decline,
and favourable changes in HDL-C level and HDL composition
may occur.16 Published data regarding the effect of TNF-α
blockers on Lp(a) are conﬂicting.19–22 Data collected in the
Table 1 Mean change from baseline to week 8* in lipid parameters (safety population)
Statistic ADA 40 mg SC q2w, n=162 TCZ 8 mg/kg IV q4w, n=162
Total cholesterol, mmol/L
Baseline
n 145 150
Mean (SD) 4.94 (1.06) 5.13 (1.11)
Change from baseline to week 8
n 129 138
Mean (SD) 0.17 (0.65) 0.79 (0.97)
Difference in adjusted means (95% CI)† 0.67 (0.47 to 0.86)
p Value‡ <0.0001
Triglycerides, mmol/L
Baseline
n 145 150
Mean (SD) 1.39 (0.69) 1.48 (0.97)
Change from baseline to week 8
n 129 138
Mean (SD) 0.07 (0.47) 0.29 (0.68)
Difference in adjusted means (95% CI)† 0.24 (0.10–0.38)
p Value‡ 0.0008
HDL-C, mmol/L
Baseline
n 145 149
Mean (SD) 1.52 (0.38) 1.56 (0.48)
Change from baseline to week 8
n 129 137
Mean (SD) 0.07 (0.25) 0.14 (0.31)
Difference in adjusted means (95% CI)† 0.07 (0.001 to 0.14)
p Value‡ 0.0453
LDL-C, mmol/L
Baseline
n 144 146
Mean (SD) 2.78 (0.89) 2.88 (0.87)
Change from baseline to week 8
n 128 133
Mean (SD) 0.07 (0.53) 0.52 (0.79)
Difference in adjusted means (95% CI)† 0.46 (0.30 to 0.62)
p Value‡ <0.0001
Total cholesterol/HDL ratio
Baseline
n 145 149
Mean (SD) 3.40 (0.97) 3.51 (1.11)
Change from baseline to week 8
n 129 137
Mean (SD) –0.01(0.51) 0.24 (0.71)
Difference in adjusted means (95% CI)† 0.27 (0.12 to 0.42)
p Value‡ 0.0005
*Includes only patients with both baseline and week 8 worst fasting values.
†Difference and 95% CI were based on adjusted least square means (TCZ-ADA).
‡ANCOVA model was adjusted for baseline laboratory parameter. p Values were unadjusted for multiple testing; therefore, no statistical significance can be claimed.
ADA, adalimumab; ANCOVA, analysis of covariance; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; IV, intravenous; LDL, low-density lipoprotein; LDL-C,
low-density lipoprotein cholesterol; q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab.
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ADACTA study allowed, for the ﬁrst time, a direct comparison
of the effect of anti-TNF (aTNF) and anti–IL-6 therapies on
lipids and lipid-associated CV risk biomarkers in the context of
a single study in which other trial parameters were balanced
between groups by strict randomisation and blinding. Post-hoc
analyses showed a greater increase in LDL-C and greater reduc-
tions in Lp(a), HDL-SAA and sPLA2 IIA levels over the ﬁrst
8 weeks of treatment in patients with RA who received TCZ
monotherapy compared with those who received adalimumab
monotherapy. Reductions in HDL-SAA, sPLA2 IIA and Lp(a)
were observed in efﬁcacy responders and non-responders, sug-
gesting that the cytokines themselves—as opposed to, or at least
in addition to, other disease activity-related pathways—mediate
some of the effects observed. Although reductions for both
responders and non-responders treated with TCZ monotherapy
appear to be larger than for those treated with adalimumab
monotherapy, the small sample size for each group precludes
statistical comparison.
Increased inﬂammation in patients with autoimmune disor-
ders such as RA is associated with quantitative and qualitative
modiﬁcations of circulating lipids. Recent data suggest that
decreased LDL-C and HDL-C levels in patients with active RA
are associated with increased cholesterol catabolism rather than
decreased synthesis, with the reverse true following treatment of
inﬂammation.28 These data are somewhat reassuring.
Nevertheless, it should be noted that parallel lipid kinetic data
do not exist for TCZ or for aTNF therapies. In addition to
Table 2 Change from baseline to week 8* in HDL-SAA and sPLA2
IIA (bio-repository population)
ADA 40 mg
SC q2w, n=97
TCZ 8 mg/kg
IV q4w, n=87 p Value†
HDL-SAA (mg/L)
Baseline
Median (IQR) 7.8 (4.0, 16.8) 6.9 (3.0, 13.9)
Mean (SD) 16.8 (23.6) 13.0 (19.2)
n=64 n=58
Change from baseline to week 8
Median (IQR) –1.1 (–7.1, 0.6) –3.2 (–11.1, –1.0) 0.0077
Mean (SD) –4.4 (12.3) –9.3 (18.3)
n=62 n=55
sPLA2 IIA (ng/mL)
Baseline
Median (IQR) 6.8 (5.1, 10.2) 7.2 (4.7, 12.2)
Mean (SD) 10.7 (12.4) 2.1 (14.8)
n=90 n=77
Change from baseline to week 8
Median (IQR) –1.3 (–2.9, 0.8) –4.1 (–7.8, –1.1) <0.0001
Mean (SD) –1.8 (9.15) –7.8 (12.8)
n=86 n=73
n represents number of patients contributing to summary statistics.
*Includes only patients with both baseline and week 8 values.
†Comparison between medians (ADA vs TCZ) using the Kruskal–Wallis test.
ADA, adalimumab; HDL-SAA, high-density lipoprotein-associated serum amyloid A; IV,
intravenous; q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; sPLA2 IIA,
secretory phospholipase A2 II; TCZ, tocilizumab.
Figure 1 Change from baseline to week 8 in HDL-SAA (A, bio-repository population), sPLA2 IIA (B, bio-repository population) and Lp(a) (C, safety
population)—patient-level data. ADA, adalimumab; HDL-SAA, high-density lipoprotein-associated serum amyloid A; IV, intravenous; Lp(a),
lipoprotein (a); sPLA2 IIA, secretory phospholipase A2 IIA; q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab.
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quantitative changes, inﬂammation may be accompanied by
changes in lipid particle size and protein composition that may
result in a potentially pro-atherogenic lipid proﬁle. In particular,
SAA, sPLA2 IIA and cholesteryl ester transfer protein can
remodel the lipid and protein composition of HDL particles.29
Association of HDL with SAA and sPLA2 IIA impairs antioxida-
tive and atheroprotective capacity of HDL.30 Displacement of
HDL cargo proteins that have antioxidant activity, such as
apoA1 and paraoxonase 1, with these acute-phase reactants
results in HDL particles with pro-oxidant capacity.31
SAA-containing HDL may be retained in the vascular matrix by
vascular proteoglycans and may therefore not be available for
the reverse cholesterol transport.32
Elevated Lp(a) levels can contribute to atherogenesis by
depositing LDL-C in the intima of the vascular wall by the
recruitment of inﬂammatory cells or the binding of proinﬂam-
matory oxidised phospholipids. Lp(a) shares structural hom-
ology with plasminogen and plasmin and has potentially
prothrombotic and anti-ﬁbrinolytic properties, which could
promote clot stabilisation and thrombosis.27 Recent data suggest
that Lp(a) is an independent genetic risk marker of CVD and is
potentially causal.13 It has been recommended that desirable
levels of Lp(a) for patients at intermediate or high risk of CVD/
CHD are <50 mg/dL.27
The observation that reductions in HDL-SAA, sPLA2 IIA and
Lp(a) occurred in non-responders suggests that the reduction in
these potentially pro-atherogenic proteins with TCZ may be, at
least partially, independent of the RA treatment response,
reﬂecting the effect of IL-6 blockade outside the joint. IL-6 is
known to have an effect on the release of acute-phase proteins
from hepatocytes; SAA is increased and apoA1 is decreased.31 33
Synthesis of Lp(a) is increased in response to IL-6 in cultured
human hepatocytes through direct regulation of a response
element in the Lp(a) promoter, an effect that was inhibited by
TCZ.34 Therefore, the results of the current analysis may be
explained by an effect of IL-6 inhibition that is independent of
its anti-arthritic effect, similar to its effect on C reactive protein
production.35 Decreases in HDL-SAA, sPLA2 IIA and Lp(a)
levels also occurred in adalimumab non-responders; although
they appeared to have occurred to a lesser extent than in TCZ
Table 4 Change from baseline to week 8* in HDL-SAA and sPLA2
IIA for week 24 ACR20, ACR50 and EULAR good/moderate
responders and non-responders (bio-repository population)
Subgroup Statistic
ADA 40 mg SC
q2w, n=97
TCZ 8 mg/kg
IV q4w, n=87
HDL-SAA change from baseline to week 8 (mg/L)
ACR20 responders
n 32 39
Median (IQR) –1.0 (–6.8, 0.55) –3.3 (10.0, –1.0)
Mean (SD) –5.8 (12.5) –10.3 (21.1)
ACR20 non-responders
n 30 16
Median (IQR) –1.1 (–8.7, 1.2) –3.1 (–12.95, –1.15)
Mean (SD) –2.9 (12.1) –7.1 (7.8)
ACR50 responders
n 20 26
Median (IQR) –1.6 (–6.6, 0.25) –3.3 (–8.6, –1.0)
Mean (SD) –5.1 (11.2) –11.8 (25.1)
ACR50 non-responders
n 42 29
Median (IQR) –0.9 (–7.10, 0.7) –3.2 (–12.8, –1.0)
Mean (SD) –4.0 (12.9) –7.2 (8.4)
EULAR good/moderate responders
n 36 45
Median (IQR) –2.8 (–9.05, 0.5) –3.2 (–10.0, –1.0)
Mean (SD) –6.2 (12.3) –9.6 (19.8)
EULAR non-responders
n 26 10
Median (IQR) –0.5 (–5.7, 1.2) –2.9 (–18.2, –1.3)
Mean (SD) –1.9 (12.1) –8.0 (8.9)
sPLA2 IIA change from baseline to week 8 (ng/mL)
ACR20 responders
n 47 52
Median (IQR) –1.3 (–3.2, 0.7) –4.8 (–9.5, –1.3)
Mean (SD) –1.6 (8.3) –9.5 (14.8)
ACR20 non-responders
n 39 21
Median (IQR) –0.6 (–2.8, 1.9) –3.1 (–4.9, –1.0)
Mean (SD) –2.0 (10.2) –3.7 (2.7)
ACR50 responders
n 24 36
Median (IQR) –1.8 (–2.6, 0.2) –5.0 (–9.5, –0.95)
Mean (SD) –1.6 (2.5) –9.7 (13.9)
ACR50 non-responders
n 62 37
Median (IQR) –1.0 (–3.2, 1.4) –4.0 (–6.7, –1.5)
Mean (SD) –1.9 (10.7) –6.1 (11.5)
EULAR good/moderate responders
n 53 62
Median (IQR) –1.6 (–3.2, 0.7) –4.7 (–9.1, –1.1)
Mean (SD) –2.2 (9.8) –8.7 (13.7)
EULAR non-responders
n 33 11
Median (IQR) –0.2 (–2.1, 1.9) –2.7 (–6.0, –0.8)
Mean (SD) –1.2 (8.1) –3.2 (2.4)
n represents number of patients contributing to summary statistics.
The range of data for each parameter is depicted in figure 1.
*Includes only patients with both baseline and week 8 values.
ACR, American College of Rheumatology; ADA, adalimumab; EULAR, European League
against Rheumatism; HDL-SAA, high-density lipoprotein-associated serum amyloid-A; IV,
intravenous; q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; sPLA2 IIA,
secretory phospholipase A2 IIA; TCZ, tocilizumab.
Table 3 Change from baseline to week 8* in Lp(a) for all patients
(safety population)
Subgroup Statistic
ADA 40 mg
SC q2w, n=162
TCZ 8 mg/kg
IV q4w, n=162
Lp(a) (mg/dL)
Baseline
n 162 162
Mean (SD) 25.5 (30.2) 22.4 (25.5)
min, max 4.0, 194.0 4.0, 131.0
Change from baseline to week 8
n 157 156
Mean (SD) –1.1 (15.1) –7.6 (12.0)
min, max –102.5, 86.4 –60, 21.9
Difference in
adjusted means (95% CI)†
–7.12 (–9.9 to –4.4)
p Value‡ <0.0001
*Includes only patients with both baseline and week 8 values.
†Difference and 95% CI based on adjusted least square means (TCZ-ADA).
‡ANCOVA model was adjusted for baseline Lp(a). p Values were unadjusted for multiple
testing; therefore, no statistical significance can be claimed.
ADA, adalimumab; ANCOVA, analysis of covariance; IV, intravenous; Lp(a), lipoprotein
(a); q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab.
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non-responders, the numbers were too small to make a statis-
tical comparison. In contrast, results from a recent cohort study
of patients with RA treated with TNF-α inhibitors, including
adalimumab, showed that HDL-SAA was signiﬁcantly decreased
and that ApoAII was increased in EULAR good responders but
not in non-responders, suggesting that the changes were due to
the anti-inﬂammatory effect of TNF-α inhibition.36
Furthermore, no change in Lp(a) levels was observed in patients
with RA treated with adalimumab for 3 months, and adalimu-
mab did not have a direct effect on Lp(a) promoter activity in
human hepatocytes, as was observed with TCZ.34 The small
number of patients in the current analysis preclude statistical
comparison between responders and non-responders in each
treatment group, and larger studies would be required to investi-
gate mechanisms of IL-6 and TNF-α effects on HDL-SAA,
sPLA2 IIA and Lp(a).
Limitations of this data analysis from the ADACTA study are
that it was conducted post-hoc and that the treatment duration
analysed was relatively short. Longer-term effects on lipid
changes were not investigated, though these same effects seen at
week 8 have been seen previously with TCZ treatment out to
24 weeks;16 nevertheless, the effect on CV risk cannot be deter-
mined. It is unknown whether the changes in lipid proﬁles and
the reductions in Lp(a), HDL-SAA and sPLA2 IIA levels
observed with TCZ treatment and the differences observed in
treatment with adalimumab will have any implications on CV
risk in patients with RA. Results from meta-analyses of mostly
observational studies suggest that aTNF therapy for RA is likely
associated with a decreased CV risk despite increases in lipid
levels.37 38 Although the risk of CV events with TCZ has not
been determined, the number of CV events in the placebo-
controlled periods of the core TCZ Phase III trials was low. In
addition, long-term data available to date have shown a stable
rate of CV events over time with TCZ exposure.25 Furthermore,
risk of on-treatment major adverse CV events was found to be
associated with control of disease activity, but not lipid changes,
in a retrospective post-hoc analysis of pooled data from trials,
though admittedly the number of adjudicated events was
modest.39 Clearly, studies designed speciﬁcally to compare the
effects of biologics on lipid changes and CV outcomes are still
required.
In conclusion, despite the overall increased LDL-C levels
observed with TCZ compared with adalimumab, TCZ may
potentially exert beneﬁcial actions on HDL-SAA, sPLA2 IIA and
Lp(a), suggesting that IL-6 blockade may work in different ways
to inﬂuence CVD risk.
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